Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Meric

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|February 28, 2004
Metastatic malignant melanomaJ B Meric, O Rixe, D Khayat
Bulletin Du Cancer|April 27, 2010
[New therapeutics strategies in renal cell carcinoma]J-B Meric, B Billemont, O Rixe
Abdominal Imaging|February 20, 2003
Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiographyM F Bellin, L Lebleu, J B Meric
Current Medical Research and Opinion|November 26, 2005
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapyJ Bloch, O Rixe, J B Meric, et al.
Bulletin Du Cancer|May 13, 2009
[Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma]L Taillade, I Alexandre, B Billemont, et al.
British Journal of Cancer|October 9, 2008
Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinibB Billemont, J Medioni, L Taillade, et al.
Bulletin Du Cancer|February 15, 2001
[Zd 1839 "Iressa"]J B Meric, S Faivre, C Monnerat, et al.
Current Oncology (Toronto, Ont.)|December 15, 2010
Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trialH Assi, G Missenard, P Terrier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 27, 2008
[Neoadjuvant therapy for renal cancer]F Thibault, O Rixe, J-B Meric, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2011
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)T C Gauler, B Besse, A Mauguen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Drugs of Today (Barcelona, Spain : 1998)|February 28, 2004
Metastatic malignant melanomaJ B Meric, O Rixe, D Khayat
Bulletin Du Cancer|April 27, 2010
[New therapeutics strategies in renal cell carcinoma]J-B Meric, B Billemont, O Rixe
Abdominal Imaging|February 20, 2003
Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiographyM F Bellin, L Lebleu, J B Meric
Current Medical Research and Opinion|November 26, 2005
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapyJ Bloch, O Rixe, J B Meric, et al.
Bulletin Du Cancer|May 13, 2009
[Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma]L Taillade, I Alexandre, B Billemont, et al.
British Journal of Cancer|October 9, 2008
Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinibB Billemont, J Medioni, L Taillade, et al.
Bulletin Du Cancer|February 15, 2001
[Zd 1839 "Iressa"]J B Meric, S Faivre, C Monnerat, et al.
Current Oncology (Toronto, Ont.)|December 15, 2010
Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trialH Assi, G Missenard, P Terrier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 27, 2008
[Neoadjuvant therapy for renal cancer]F Thibault, O Rixe, J-B Meric, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2011
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)T C Gauler, B Besse, A Mauguen, et al.
Pageof 1